Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo

Li,Min; Yin,Jie; Mao,Ning; Pan,Lingya

doi:10.3892/or.2012.2078

Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo

Authors:
- Min Li
- Jie Yin
- Ning Mao
- Lingya Pan
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijing Hospital, Dongdan, Beijing 100730, P.R. China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, P.R. China, Department of Cell Biology, Institute of Basic Medical Science, Beijing 100850, P.R. China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730
Published online on: October 12, 2012 https://doi.org/10.3892/or.2012.2078
Pages: 58-66

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The acquisition of chemoresistance is a major therapeutic obstacle in the clinical treatment of ovarian cancer. Diagnosing chemoresistance in ovarian cancer patients at an early stage is necessary for prognosis, but at present significant proteins related to chemoresistance that may indicate and reverse chemoresistance in human ovarian cancer have not been discovered. In this study, we demonstrated that the protein, phosphorylated cofilin 1 (p-CFL1) correlates with taxol resistance in human ovarian cancer cells. The total proteins of two sensitive (SKOV3 and A2780) and three taxol-resistant (SKOV3/TR2500, SKOV3/TR30 and A2780/TR) human ovarian cancer cell lines were isolated by 2-dimensional gel electrophoresis (2-DE). Twenty-two protein spots in all samples were revealed to be significantly different in spot intensity by statistical analysis, 16 of which were identified using matrix-assisted laser desorption ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS). Cofilin 1 (CFL1) was selected as a candidate which may play an important role in taxol resistance. Higher expression levels of p-CFL1 in taxol-resistant cells were demonstrated. Furthermore, the levels of p-CFL1 in primary human ovarian cancer tissues were shown to be significantly higher in chemoresistant cases compared to those in chemosensitive ones. These findings suggest that p-CFL1 is upregulated in taxol-resistant ovarian cancer and this upregulation is a characteristic of taxol resistance both in vitro and in vivo. However, the mechanisms need to be further elucidated.

View Figures

View References

1	Cicchillitti L, Della Corte A, Di Michele M, Donati MB, Rotilio D and Scambia G: Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: The involvement of specific conformational states of β-actin. Int J Oncol. 37:445–454. 2010.PubMed/NCBI
2	Bovicelli A, D’Andrilli G and Giordano A: New players in ovarian cancer. J Cell Physiol. 226:2500–2504. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kurman RJ and Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kim A, Ueda Y, Naka T and Enomoto T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 31:142012. View Article : Google Scholar : PubMed/NCBI
5	Rein DT, Volkmer A, Bauerschmitz G, et al: Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. J Cancer Res Clin Oncol. 138:603–610. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010. View Article : Google Scholar : PubMed/NCBI
7	Umezu T, Shibata K, Kajiyama H, et al: Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol. 27:207–212. 2008.PubMed/NCBI
8	Wang Y, Chen Q, Jin S, et al: Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells. Scand J Gastroenterol. 47:802–808. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yan XD, Li M, Yuan Y, Mao N and Pan LY: Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep. 17:1163–1169. 2007.PubMed/NCBI
10	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
11	Preusser M, Spiegl-Kreinecker S, Lötsch D, et al: Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. March 5–2012.(Epub ahead of print). View Article : Google Scholar
12	Gorg A, Obermaier C, Boguth G, et al: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 21:1037–1053. 2000. View Article : Google Scholar : PubMed/NCBI
13	Yan XD, Pan LY, Yuan Y, Lang JH and Mao N: Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res. 6:772–780. 2007. View Article : Google Scholar
14	Joubert-Caron R, Le Caer JP, Montandon F, et al: Protein analysis by mass spectrometry and sequence database searching: a proteomic approach to identify human lymphoblastoid cell line proteins. Electrophoresis. 21:2566–2575. 2000. View Article : Google Scholar : PubMed/NCBI
15	Swenerton K, Muss H and Robinson E: Salvage Chemotherapy for Refractory Disease. Ovarian Cancer Controversies on Management. Gershenson DM and McGuire WP: Churchill Livingstone; New York: pp. 169–194. 1998
16	Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 29:577–580. 1981. View Article : Google Scholar : PubMed/NCBI
17	Beamer LC, Grant ML, Espenschied CR, et al: Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 30:1058–1063. 2012. View Article : Google Scholar
18	Tanaka Y, Fujiwara K, Tanaka H, Maehata K and Kohno I: Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. Int J Gynecol Cancer. 14:616–620. 2004. View Article : Google Scholar : PubMed/NCBI
19	Alli E, Yang JM, Ford JM and Hait WN: Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 71:1233–1240. 2007. View Article : Google Scholar : PubMed/NCBI
20	Song TF, Zhang ZF, Liu L, Yang T, Jiang J and Li P: Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). J Int Med Res. 37:1375–1388. 2009. View Article : Google Scholar
21	Balasubramani M, Nakao C, Uechi GT, et al: Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis. Mutat Res. 722:154–164. 2011. View Article : Google Scholar
22	Estornes Y, Gay F, Gevrey JC, et al: Differential involvement of destrin and cofilin-1 in the control of invasive properties of Isreco1 human colon cancer cells. Int J Cancer. 121:2162–2171. 2007. View Article : Google Scholar : PubMed/NCBI
23	Castro MA, Dal-Pizzol F, Zdanov S, et al: CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer. Cancer. 116:3645–3655. 2010. View Article : Google Scholar : PubMed/NCBI
24	Muller CB, de Barros RL, Castro MA, et al: Validation of cofilin-1 as a biomarker in non-small cell lung cancer: application of quantitative method in a retrospective cohort. J Cancer Res Clin Oncol. 137:1309–1316. 2011. View Article : Google Scholar : PubMed/NCBI
25	Nishimura S, Tsuda H, Kataoka F, et al: Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy. Hum Pathol. 42:516–521. 2011. View Article : Google Scholar : PubMed/NCBI
26	Vartiainen MK, Mustonen T, Mattila PK, et al: The three mouse actin-depolymerizing factor/cofilins evolved to fulfill cell-type-specific requirements for actin dynamics. Mol Biol Cell. 13:183–194. 2002. View Article : Google Scholar : PubMed/NCBI
27	Dai YP, Bongalon S, Mutafova-Yambolieva VN and Yamboliev IA: Distinct effects of contraction agonists on the phosphorylation state of cofilin in pulmonary artery smooth muscle. Adv Pharmacol Sci. 2008:3627412008.PubMed/NCBI
28	Klamt F, Zdanov S, Levine RL, et al: Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol. 11:1241–1246. 2009. View Article : Google Scholar : PubMed/NCBI
29	Bernstein BW and Bamburg JR: ADF/cofilin: a functional node in cell biology. Trends Cell Biol. 20:187–195. 2010. View Article : Google Scholar : PubMed/NCBI
30	Teng B, Lukasz A and Schiffer M: The ADF/cofilin-pathway and actin dynamics in podocyte injury. Int J Cell Biol. 2012:3205312012. View Article : Google Scholar : PubMed/NCBI
31	Ruegg J, Holsboer F, Turck C and Rein T: Cofilin 1 is revealed as an inhibitor of glucocorticoid receptor by analysis of hormone-resistant cells. Mol Cell Biol. 24:9371–9382. 2004. View Article : Google Scholar : PubMed/NCBI
32	Scott RW, Hooper S, Crighton D, et al: LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol. 191:169–185. 2010. View Article : Google Scholar : PubMed/NCBI